MedTrace Logo

M89PF in Rosacea Associated With Erythema and Sensitive Skin

NCT05562661 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2022-10-03

No results posted yet for this study

Summary

Rosacea is a common facial dermatosis, with flares induced by exposome factors. M89PF containing Vichy mineralizing water, probiotic fractions, hyaluronic acid, niacinamide and tocopherol repairs the skin barrier and reinforces skin defences against exposome factors.

This study assessed the benefit of M89PF in patients with rosacea associated with erythema and sensitive skin during the Covid-19 pandemic with use of protective face masks.

Conditions

  • Rosacea

Sponsors & Collaborators

  • Cosmetique Active International

    lead INDUSTRY

Principal Investigators

  • Delphine Kerob, MD · Laboratoires Vichy, Levallois-Perret France

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-02
Primary Completion
2021-02-28
Completion
2021-02-28

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05562661 on ClinicalTrials.gov